[REVISION HISTORY]

Bundibugyo Ebola vaccine trials

Updated 1 time since CLSTR started tracking revisions of this situation.

What changed

2026-08-04 16:08 UTC → 2026-08-04 19:26 UTC · added ~~removed~~

In late July 2026, the Oxford Vaccine Group administered the first dose of its ChAdOx1 BDBV vaccine to a healthy British volunteer, marking the start of a Phase 1 safety and immunogenicity study. The adenoviral‑vector vaccine targets the Bundibugyo strain of Ebola, for which no licensed vaccine exists, and is backed by 600,000 doses produced by the Serum Institute of India in anticipation of successful results. The trial follows a worsening Bundibugyo Ebola outbreak in the Democratic Republic of the Congo, declared a public‑health emergency with over 2,500 confirmed cases and 1,000 deaths. A week later, Moderna began its own Phase 1 trial of the mRNA‑1469 vaccine in Canada, enrolling about 80 adults across three sites. The study, approved by Health Canada, aims to assess safety and immune response. Moderna’s effort is supported by CEPI, which has pledged up to $50 million for early testing and manufacturing, and the company plans to make at least 500,000 doses available to low‑ and middle‑income countries at access pricing if approved. Updated outbreak figures cite 3,748 confirmed cases and 1,657 deaths in the DRC, underscoring the urgent need for multiple vaccine candidates. ~~Together, these parallel trials illustrate~~ On 4 August 2026, the first volunteer in Moderna’s Canadian trial received the mRNA‑1469 dose in Truro, Nova Scotia, confirming the study’s launch at three locations—Truro, Halifax and Toronto. The trial proceeds alongside the Oxford vaccine effort, reflecting a rapid, multinational push to develop effective vaccines against the Bundibugyo Ebola strain amid a severe epidemic in Central Africa.

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.